8-K: Repare Shareholders Approve XenoTherapeutics Acquisition

Repare Therapeutics shareholders overwhelmingly approved the acquisition of the company by XenoTherapeutics, Inc. via a plan of arrangement.

Summary

• Repare Therapeutics Inc. held a Special Meeting on January 16, 2026, where a quorum was present.
• Shareholders approved a plan of arrangement for Xeno Acquisition Corp. to acquire all issued and outstanding common shares of Repare Therapeutics.
• The Arrangement Resolution was approved by 99.76% of the votes cast by shareholders, both including and excluding votes required to be excluded by Multilateral Instrument 61-101.
• Shareholders also approved, on an advisory and non-binding basis, the compensation to be paid to named executive officers related to the Arrangement by 99.34% of votes cast.
• Contingency resolutions for the voluntary liquidation and dissolution of the Company, and the appointment of KPMG LLP as liquidator, were approved by 99.75% of votes cast, in the event the Arrangement is terminated.
• The Arrangement is subject to the approval of the Superior Court of Quebec, with a hearing expected on January 23, 2026.
• Assuming court approval and satisfaction of other customary closing conditions, the completion of the Arrangement is expected to occur on or about January 28, 2026.

Sentiment

Score: 8

Explanation: The overwhelming shareholder approval for the acquisition and related resolutions indicates a clear path forward for the company, either through the acquisition or an orderly liquidation. This reduces uncertainty for investors regarding the company's immediate future, even if it means the end of its independent public existence. The high approval rates suggest the terms were acceptable to a vast majority of shareholders.

Positives

• Overwhelming shareholder approval (99.76%) for the acquisition by XenoTherapeutics, indicating strong support for the transaction.
• Shareholders also approved executive compensation related to the arrangement (99.34%), suggesting alignment with management's proposed terms.
• Contingency plans for liquidation and liquidator appointment were approved, providing a clear path forward even if the acquisition fails, ensuring orderly corporate governance.

Negatives

• The company will cease to exist as an independent publicly traded entity upon completion of the acquisition, potentially limiting future growth opportunities for current shareholders beyond the acquisition terms.

Risks

• The completion of the Transaction on anticipated terms and timing, including obtaining required Court approvals, and the satisfaction of other conditions.
• Potential litigation relating to the Transaction that could be instituted by or against the Company, Xeno, XOMA Royalty Corporation or their respective directors or officers.
• Disruptions from the Transaction harming the Company's business, including current plans and operations.
• The ability of the Company to retain and hire key personnel.
• Potential adverse reactions or changes to business relationships resulting from the announcement or completion of the Transaction.
• Continued availability of capital and financing and rating agency actions.
• Legislative, regulatory and economic developments affecting the Company's business.
• The accuracy of the Company's financial projections.
• General business, market and economic conditions.
• Certain restrictions during the pendency of the Transaction that may impact the Company's ability to pursue certain business opportunities or strategic transactions.
• Unpredictability and severity of catastrophic events, including but not limited to acts of terrorism, pandemics, outbreaks of war or hostilities.
• Significant transaction costs associated with the Transaction.
• The possibility that the Transaction may be more expensive to complete than anticipated, including as a result of unexpected factors or events.
• Competitive responses to the Transaction.

Future Outlook

The company anticipates the Superior Court of Quebec will approve the Arrangement on January 23, 2026, with the transaction expected to close around January 28, 2026, subject to customary closing conditions.

Management Comments

• Repare Therapeutics Inc. announced that its Shareholders have approved the acquisition of all issued and outstanding common shares by XenoTherapeutics, Inc. and Xeno Acquisition Corp. by way of a statutory plan of arrangement.

Industry Context

Repare Therapeutics is a clinical-stage precision oncology company focused on synthetic lethality and DNA damage repair. XenoTherapeutics, Inc. is a non-profit biotechnology company focused on advancing xenotransplantation. This acquisition represents a shift for Repare's assets into a non-profit structure, potentially indicating a strategic pivot for the acquired assets or a different funding model for their development, moving them out of the traditional for-profit public biotech sphere. The acquisition by a non-profit suggests a focus on research and development rather than immediate commercial returns, which is an unusual but not unheard-of transaction in the biotech space, especially for clinical-stage assets.

Corporate Governance

Stakeholder Impact

• Shareholders: Will receive consideration for their shares as part of the acquisition by Xeno Acquisition Corp. or face liquidation if the arrangement fails. The overwhelming vote suggests satisfaction with the proposed outcome.
• Employees: The risk section mentions potential disruptions and challenges in retaining key personnel, implying an impact on employees.
• Management: Executive officers will receive compensation related to the Arrangement, which was approved by shareholders.
• Customers/Partners: The acquisition by a non-profit focused on xenotransplantation could alter the strategic direction for Repare's oncology assets, potentially impacting existing or future partnerships.

Next Steps

• Court hearing for the final order to approve the Arrangement on January 23, 2026.
• Completion of the Arrangement expected on or about January 28, 2026.

Key Dates

Recommendation

The company is in the final stages of an acquisition, with shareholder approval secured and court approval pending. The transaction is expected to close within weeks. At this stage, the share price is likely to trade very close to the acquisition price, offering little upside for new investors and making a 'hold' recommendation appropriate for existing shareholders awaiting the transaction's completion. A 'buy' would be speculative on a slight arbitrage, and 'sell' would be premature before the final closing.

Keywords

Repare Therapeutics, RPTX, XenoTherapeutics, Xeno Acquisition Corp., acquisition, merger, plan of arrangement, shareholder vote, oncology, biotechnology, precision oncology, synthetic lethality, clinical-stage, corporate governance, SEC filing, 8-K